OSEBX1,423.56+0.84%
EQNR284.60+4.20%
DNB198.35-1.15%
MOWI172.80+0.45%
Brent$71.24-0.32%
EUR/USD1.0824-0.14%
DXY104.18+0.08%
INDICATIVE · SAMPLE DATA
EMD55

Emyria Ltd

Biotechnology & Medical ResearchVerified

Emyria's capital structure is characterized by a lack of detailed liquidity metrics, as no balance-sheet inputs are available and there is no going-concern language in the source documents. This absence of data prevents a comprehensive assessment of the company's liquidity position. Profitability and return metrics are not available for Emyria, as the valuation snapshot does not provide data on return on invested capital (ROIC), margins, or other key performance indicators. Without these metrics, it is not possible to compare Emyria's performance against industry benchmarks or the median for its sector. Segment and geographic exposure data are not disclosed in the available financial information. As a result, it is not possible to assess the company's revenue concentration or geographic diversification. This lack of transparency limits the ability to evaluate the company's exposure to regional economic or regulatory risks. Growth trajectory data is also limited. The outlook for the current and next fiscal years does not include numeric deltas or revenue history, making it difficult to assess Emyria's growth potential or performance trends over time. Risk factors for Emyria include a lack of liquidity data, which could indicate potential financial instability or operational constraints. The company is currently assessed as having low dilution risk, and no adjustments have been applied to the valuation metrics. However, the absence of detailed financial data limits the ability to fully evaluate the company's risk profile. Recent events and filings for Emyria are not detailed in the available data. The lack of disclosed events or transcripts prevents an assessment of recent company developments or management commentary that could impact the company's strategic direction or financial performance.

30-day price · EMD-0.42 (-3.9%)
Low$10.25High$10.97Close$10.41As of8 Jun, 00:00 UTC
Profile
CompanyEmyria Ltd
TickerEMD.AX
SectorHealthcare
BusinessPharmaceuticals & Medical Research
Industry groupPharmaceuticals & Medical Research
IndustryBiotechnology & Medical Research
AI analysis

Business. Emyria Ltd is a healthcare diagnostics company that provides diagnostic solutions and services, primarily focused on the development and commercialization of diagnostic tests for infectious diseases and other health conditions.

Classification. Emyria is classified under the Healthcare economic sector, within the Pharmaceuticals & Medical Research business sector, and the Biotechnology & Medical Research industry, with a high confidence level of 0.92.

Emyria's capital structure is characterized by a lack of detailed liquidity metrics, as no balance-sheet inputs are available and there is no going-concern language in the source documents. This absence of data prevents a comprehensive assessment of the company's liquidity position. Profitability and return metrics are not available for Emyria, as the valuation snapshot does not provide data on return on invested capital (ROIC), margins, or other key performance indicators. Without these metrics, it is not possible to compare Emyria's performance against industry benchmarks or the median for its sector. Segment and geographic exposure data are not disclosed in the available financial information. As a result, it is not possible to assess the company's revenue concentration or geographic diversification. This lack of transparency limits the ability to evaluate the company's exposure to regional economic or regulatory risks. Growth trajectory data is also limited. The outlook for the current and next fiscal years does not include numeric deltas or revenue history, making it difficult to assess Emyria's growth potential or performance trends over time. Risk factors for Emyria include a lack of liquidity data, which could indicate potential financial instability or operational constraints. The company is currently assessed as having low dilution risk, and no adjustments have been applied to the valuation metrics. However, the absence of detailed financial data limits the ability to fully evaluate the company's risk profile. Recent events and filings for Emyria are not detailed in the available data. The lack of disclosed events or transcripts prevents an assessment of recent company developments or management commentary that could impact the company's strategic direction or financial performance.
Key takeaways
  • Emyria's liquidity position cannot be assessed due to the absence of balance-sheet data and going-concern language.
  • Profitability and return metrics are not available, limiting the ability to evaluate the company's performance against industry benchmarks.
  • Segment and geographic exposure data are not disclosed, making it difficult to assess revenue concentration and regional risk.
  • Growth trajectory and revenue history are not provided, hindering the evaluation of the company's performance trends.
  • The company is assessed as having low dilution risk, but the lack of detailed financial data limits the ability to fully evaluate its risk profile.
  • Recent events and filings are not detailed, preventing an assessment of recent company developments or management commentary.
  • --
  • ## RATIONALES
Financial snapshot
PeriodHA-latest
CurrencyAUD
Revenue
Gross profit
Operating income
Net income
R&D
SG&A
D&A
SBC
Operating cash flow
CapEx
Free cash flow
Total assets
Total liabilities
Total equity
Cash & equivalents
Long-term debt
Annual history (last 5)
PeriodRevenueOp IncomeNet IncomeFCF
FY-4$2.0M-$4.9M-$4.9M-$4.6M
FY-3$1.8M-$7.3M-$7.3M-$7.0M
FY-2$1.6M-$5.1M-$5.1M-$4.7M
FY-1$2.2M-$11.5M-$11.5M-$10.9M
FY0$1.4M-$3.1M-$3.1M-$2.7M
PeriodGross %Op %Net %FCF %
FY-4
FY-3
FY-2
FY-1
FY0
PeriodAssetsEquityCashDebt
FY-4$9.1M$7.2M
FY-3$8.2M$6.3M
FY-2$10.2M$6.8M
FY-1$5.4M$2.4M
FY0$6.6M$5.3M
PeriodOCFCapExFCFSBC
FY-4-$3.9M-$8.1k-$4.6M
FY-3-$5.4M-$52.9k-$7.0M
FY-2-$3.8M-$16.8k-$4.7M
FY-1-$4.3M-$159.1k-$10.9M
FY0-$2.7M-$13.9k-$2.7M
Quarterly history (last 4)
PeriodRevenueOp IncomeNet IncomeFCF
FQ-7
FQ-6
FQ-5
FQ-4
FQ-3
FQ-2
FQ-1
FQ0
PeriodGross %Op %Net %FCF %
FQ-7
FQ-6
FQ-5
FQ-4
FQ-3
FQ-2
FQ-1
FQ0
PeriodAssetsEquityCashDebt
FQ-7
FQ-6
FQ-5
FQ-4
FQ-3
FQ-2
FQ-1
FQ0
PeriodOCFCapExFCFSBC
FQ-7
FQ-6
FQ-5
FQ-4
FQ-3
FQ-2
FQ-1
FQ0
Valuation
Market price
Market cap
Enterprise value
P/E
Reported non-GAAP P/E
EV/Revenue
EV/Op income
EV/OCF
P/B
P/Tangible book
Tangible book
Net cash
Current ratio
Debt/Equity
ROA
ROE
Cash conversion
CapEx/Revenue
SBC/Revenue
Asset intensity
Dilution ratio0.0%
Risk assessment
Dilution riskLow
Liquidity riskUnknown
  • Liquidity risk could not be assessed (no balance-sheet inputs and no going-concern language in source documents).
Industry benchmarks
Activity: Healthcare Diagnostics · cohort 170 companies
MetricEMDActivity
Op margin-227.5% medp25 -1250.6% · p75 -3.5%
Net margin-194.5% medp25 -1233.8% · p75 0.8%
Gross margin53.0% medp25 25.9% · p75 75.7%
CapEx / revenue-8.2% medp25 -35.2% · p75 -2.5%
Debt / equity1.2% medp25 0.0% · p75 17.4%
Source data
Underlying data the analysis-pipeline pulls and audits. Fetch timestamps + content hashes show when each source was last refreshed.
Company fundamentalsperiod FQ-7 · history via verified-market-data
no public URL
2026-05-08 00:33 UTC#6da5339b
Source: analysis-pipeline (hybrid)Generated: 2026-05-27 20:47 UTCJob: fe5e1e60